← Back to headlines
Merck Receives Upgrade After Cancer Trial Win, RBC Downgrades
Merck has been upgraded by Morgan Stanley following a successful cancer trial, with analysts citing a strong cancer drug pipeline. However, RBC has downgraded the company, indicating differing perspectives on its future.
20 Aug, 12:01 — 20 Aug, 14:22
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (27/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left1
Left (1)
cnbc
Center
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
cnbcMostly Factual3h ago
Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says
Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.
Read full article →seeking-alphaMixed1h ago
Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
Read full article →Coverage Timeline
First report: cnbc · 20 Aug, 12:01|Full coverage: 2 · 2h|Window: 2h
Left-leaningCenterRight-leaning
Related Stories
Scott Bessent's Treasury Bond Market Intervention and Future Plans
15m ago
Walmart to Return $2.9 Billion Tariff Refund to Shoppers Through Price Cuts
20m ago
India Allows Duty-Free Import of 1 Million Tons of Raw Sugar to Cool Prices
23m ago
Home Depot Faces Uphill Battle Amid Growing Customer Problems
24m ago